5.3.5 Respiratory syncytial virus - South & West

All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.

Switch to N&E website

Formulary

Back

5.3 Antiviral drugs Toggle Pages

5.3.1 HIV infection 5.3.2 Herpes virus infections 5.3.3 Viral hepatitis 5.3.4 Influenza 5.3.5 Respiratory syncytial virus (RSV) 5.3.6 nMABs and other antiviral drugs

Chapter 5: Infections Toggle Parent Pages

Principles of antibacterial treatment Upper respiratory tract infections Lower respiratory tract infections Acute exacerbation of bronchiectasis (non-cystic fibrosis) Urinary tract infections (UTI) Gastro-intestinal tract infections Genital tract infections Skin and soft tissue infections Eye infections Oral and dental infections Lyme disease guidance Meningitis guidance Methicillin Resistant Staphylococcus Aureus (MRSA) guidance COVID-19 treatments for patients who do not require hospitalisation 5.1 Antibacterial drugs 5.2 Antifungal drugs 5.3 Antiviral drugs 5.4 Antiprotozoal drugs 5.5 Anthelmintics

Print this page

Page last updated:
26 July 2024

Contact us about this page

5.3.5 Respiratory syncytial virus (RSV)

First Line

Second Line

Specialist

Hospital Only

Respiratory syncytial virus (RSV) vaccines listed elsewhere in the formulary:

Abrysvo vaccine (bivalent, recombinant) (RSV) and Arexvy vaccine (recombinant, adjuvanted) (RSV), see section 14.1 Vaccines and antisera

Beyfortus

(Nirsevimab)

Solution for injection pre-filled syringe 50mg/0.5ml, 100mg/1ml

Synagis

(Palivizumab)

Solution for injection vial 50mg/0.5ml, 100mg/1ml